<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): August 2, 2000
AXYS PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Delaware 000-22788 22-2969941
------------------------------- ------------------------ -------------------------------
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer Identification
Incorporation) Number)
</TABLE>
180 Kimball Way
South San Francisco, CA 94080
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
(650) 829-1000
----------------------------------------------------
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 5. OTHER EVENTS
Axys Pharmaceuticals, Inc. announced its financial results for
the quarter ended June 30, 2000 in a press release issued on August 2, 2000.
The press release is attached hereto as Exhibit 20.1.
ITEM 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits: The following exhibits are filed as part of this Report.
20.1 Press Release, dated August 2, 2000, of Axys Pharmaceuticals,
Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: August 3, 2000
AXYS PHARMACEUTICALS, INC.
By: /s/ William J. Newell
--------------------------
William J. Newell
Senior Vice President
